> Ti 25 Pill - white capsule/oblong
Pill with imprint > Ti 25 is White, Capsule/Oblong and has been identified as Topiramate (Sprinkle) 25 mg. It is supplied by Cobalt Laboratories Inc.
Topiramate is used in the treatment of Migraine Prevention; Lennox-Gastaut Syndrome; Seizure Prevention; Epilepsy; Seizures and belongs to the drug class carbonic anhydrase inhibitor anticonvulsants. There is positive evidence of human fetal risk during pregnancy. Topiramate 25 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for > Ti 25
Topiramate (Sprinkle)
- Imprint
- > Ti 25
- Strength
- 25 mg
- Color
- White
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Carbonic anhydrase inhibitor anticonvulsants
- Pregnancy Category
- D - Positive evidence of risk
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Cobalt Laboratories Inc
- National Drug Code (NDC)
- 16252-0569 (Discontinued)
- Inactive Ingredients
-
raw sugar,
povidone k30,
saccharin sodium,
magnesium stearate,
polyvinyl alcohol,
gelatin,
titanium dioxide,
polyethylene glycol 3350,
magnesium silicate
Note: Inactive ingredients may vary.
Related images for "> Ti 25"
More about topiramate
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1,324)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: carbonic anhydrase inhibitor anticonvulsants
- Breastfeeding
Patient resources
- Topiramate drug information
- Topiramate (Advanced Reading)
- Topiramate Tablets
- Topiramate Extended-Release Sprinkle Capsules
- Topiramate Sprinkle Capsules
- Topiramate Extended-Release Capsules
Other brands
Topamax, Trokendi XR, Topamax Sprinkle, Eprontia, ... +2 more
Professional resources
- Topiramate monograph
- Topiramate (FDA)
- Topiramate Capsules (FDA)
- Topiramate ER Capsules (FDA)
- Topiramate Tablets (FDA)
Other brands
Topamax, Trokendi XR, Eprontia, Qudexy XR
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
